Linifanib
Linifanib is a small molecule inhibitor that targets multiple tyrosine kinase receptors, which are involved in the signaling pathways that regulate cell growth and angiogenesis. Linifanib is primarily researched for its potential use in the treatment of various types of cancer, including hepatocellular carcinoma (HCC), which is the most common type of liver cancer, and other solid tumors. Its mechanism of action involves the inhibition of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, which play a critical role in the angiogenesis process necessary for tumor growth and metastasis.
Mechanism of Action[edit | edit source]
Linifanib works by selectively inhibiting the activity of receptor tyrosine kinases, including VEGFR and PDGFR. By blocking these receptors, linifanib disrupts the angiogenesis process, which is essential for the growth and spread of tumors. Angiogenesis is the formation of new blood vessels from pre-existing vessels and is a critical process in the progression of cancer. By inhibiting this process, linifanib aims to starve the tumor of the necessary nutrients and oxygen needed for its growth.
Clinical Trials[edit | edit source]
Linifanib has been evaluated in various clinical trials for its efficacy and safety in treating different types of cancers. One of the notable studies focused on its use in patients with advanced hepatocellular carcinoma. However, despite showing some promise in early-phase trials, linifanib has faced challenges in demonstrating a significant improvement in survival outcomes in phase III trials compared to standard treatments. The results of these studies have led to a reevaluation of the potential role of linifanib in cancer therapy.
Potential Side Effects[edit | edit source]
As with many cancer therapies, linifanib is associated with a range of potential side effects. These can include hypertension, fatigue, diarrhea, and hand-foot syndrome, among others. The severity and occurrence of these side effects vary among patients, and managing them is an important aspect of the treatment process for those receiving linifanib.
Current Status[edit | edit source]
As of April 2024, Linifanib is still being studied for treatment of hepatocellular carcinoma or any other type of cancer. Research and development efforts continue, with the aim of better understanding linifanib's mechanism of action, optimizing its therapeutic efficacy, and minimizing its side effects. The future of linifanib as a cancer treatment remains uncertain, and it is the subject of ongoing clinical research.
See Also[edit | edit source]
Transform your life with W8MD's budget GLP1 injections from $125 and up biweekly
W8MD offers a medical weight loss program NYC and a clinic to lose weight in Philadelphia. Our W8MD's physician supervised medical weight loss centers in NYC provides expert medical guidance, and offers telemedicine options for convenience.
Why choose W8MD?
- Comprehensive care with FDA-approved weight loss medications including:
- loss injections in NYC both generic and brand names:
- weight loss medications including Phentermine, Qsymia, Contrave, Diethylpropion etc.
- Accept most insurances for visits or discounted self pay cost.
- Generic weight loss injections starting from just $125.00 for the starting dose
- In person weight loss NYC and telemedicine medical weight loss options in New York city available
Book Your Appointment
Start your NYC weight loss journey today at our NYC medical weight loss, and Philadelphia and visit Philadelphia medical weight loss Call (718)946-5500 for NY and 215 676 2334 for PA
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's NYC physician weight loss.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available. Call 718 946 5500.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD